US Approvals Analysis: April A Big Month For Non-Invasive Neurostim

Two de novo go-aheads granted by FDA last month sent non-implantable neurostimulation devices to market, one for headaches and the other for tear production. Overall, the agency granted four de novos in April, continuing a strong trend this year for that marketing pathway, according to Medtech Insight's Approvals Tracker.

FDA approved background, 3D rendering, blue street sign

[Editors' note: For sortable and searchable tables of US and international approvals and clearances check out our Approvals Tracker.]

R&D into non-invasive neurostimulation devices, a market attracting serious attention and investment from both drug and device firms, showed signs...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation